| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 22061 |
| Drug | Faricimab |
| Brand | Vabysmo ® |
| Indication | For the treatment of adult patients with visual impairment due to diabetic macular oedema (DMO). |
| Assessment Process | |
| Rapid review commissioned | 29/08/2022 |
| Rapid review completed | 04/10/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of faricimab (Vabysmo®) for the treatment of DMO compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 25/10/2022 |
| Pre-submission consultation with Applicant | 03/10/2023 |
